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Abstract
Background: As The Gambia aims to achieve malaria elimination by 2030, serological assays are a useful
surveillance tool to monitor trends in malaria incidence and evaluate community-based interventions.
Methods: Within a mass drug administration (MDA) study in The Gambia, where reduced malaria infection and
clinical disease were observed after the intervention, a serological sub-study was conducted in four study villages.
Spatio-temporal variation in transmission was measured with a panel of recombinant Pf antigens on a multiplexed
bead-based assay. Village-level antibody levels were quantified as under-15 sero-prevalence, sero-conversion rates,
and age-adjusted antibody acquisition rates. Antibody levels prior to MDA were assessed for association with
persistent malaria infection after community chemoprophylaxis.
Results: Seasonal changes in antibodies to Etramp5.Ag1 were observed in children under 15 years in two transmission
settings—the West Coast and Upper River Regions (4.32% and 31.30% Pf prevalence, respectively). At the end of the
malaria season, short-lived antibody responses to Etramp5.Ag1, GEXP18, HSP40.Ag1, EBA175 RIII-V, and Rh2.2030 were
lower amongst 1–15 year olds in the West Coast compared to the Upper River, reflecting known differences in
transmission. Prior to MDA, individuals in the top 50th percentile of antibody levels had two-fold higher odds of clinical
malaria during the transmission season, consistent with previous findings from the Malaria Transmission Dynamics
Study, where individuals infected before the implementation of MDA had two-fold higher odds of re-infection post-
MDA.
Conclusions: Serological markers can serve dual functions as indicators of malaria exposure and incidence. By
monitoring age-specific sero-prevalence, the magnitude of age-stratified antibody levels, or identifying groups of
individuals with above-average antibody responses, these antigens have the potential to complement conventional
malaria surveillance tools. Further studies, particularly cluster randomised trials, can help establish standardised
serological protocols to reliably measure transmission across endemic settings.
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Background
In malaria elimination settings, heterogeneity and hot-
spots of transmission are increasingly prevalent as dis-
ease burden declines [1–5]. At low transmission, large
proportions of the population can remain malaria free
for years, while subpopulations experience multiple epi-
sodes [3, 4, 6]. This presents significant challenges for
the implementation of malaria interventions and clinical
trials designed to evaluate them [7, 8]; if untargeted, re-
sidual transmission is likely to persist [5, 9–11]. There-
fore, understanding why malaria has significantly
changed in some settings, but remains unyielding in
others, will be critical for guiding investments in malaria
control in sub-Saharan Africa [12, 13].
The Gambia has a long history of research on the het-
erogeneity of malaria in West Africa. Entomological and
clinical data have shown spatial variation in malaria in-
fections within 2 km of mosquito breeding sites, where
immune differences between households were hypothe-
sised to drive differences in clinical outcomes [14]. Stud-
ies in The Gambia have also demonstrated the impact of
insecticide-treated bed nets on childhood mortality [15,
16], with additional reductions in clinical malaria when
combined with chemoprophylaxis [17]. Subsequently,
there have been rapid declines in incidence through the
scale-up of control interventions—improved diagnosis
and treatment, distribution of long-lasting insecticidal
nets, indoor residual spraying, and seasonal malaria che-
moprevention. However, micro-epidemiological varia-
tions in transmission remain [18, 19], which are
increasingly relevant as The Gambia aims for malaria
elimination by 2030. Sufficiently sensitive diagnostics
will be critical to reach this target, helping to identify
foci of transmission and target interventions.
Serological studies in The Gambia have described
country-wide heterogeneities in malaria transmission.
School surveys have found strong correlations between
sero-prevalence and microscopy-detectable parasitaemia
[20]. More recently, studies based on data from Uganda
and Mali have identified several serological markers of
Plasmodium falciparum (Pf) malaria exposure that are
able to predict clinical infection in the previous year
with a high degree of accuracy [21]. These measures of
sero-incidence have the potential to supplement existing
surveillance tools to monitor transmission and evaluate
the effectiveness of community interventions.
While serology has been used in research settings to
measure malaria transmission for some time, standar-
dised antigen panels for routine surveillance have yet to
be established. Furthermore, gaps in our understanding
of how antibody levels reflect changes in transmission
still remain. Therefore, this study evaluates the use of
antibody responses as a measure of malaria exposure
and incidence, with the aim to inform the future design
of surveillance strategies. We used serological markers
to measure spatio-temporal variation in transmission in
a subset of four study villages from the Malaria Trans-
mission Dynamics Study in The Gambia, which assessed
epidemiological trends in six village pairs [18, 19],
followed by 2 years of mass drug administration (MDA)
with dihydroartemisnin-piperaquine (DHA-PQ) [22]. A
panel of recombinant Pf antigens was used to quantify
antibody levels with a multiplexed immuno-assay. In our
previous analysis in The Gambia, a number of targets in
this antigen panel were found to be highly correlated
with clinical and asymptomatic infection at the individ-
ual, household, and village level [23], and were also able
to measure seasonal and geographical differences in
transmission. This study builds on these findings to de-
velop standardised methods for assessing population-
level changes in antibody responses as a proxy for mal-
aria transmission. Village serological profiles were used
to describe seasonal and geographical variation in anti-
body responses, and the association between antibody
levels prior to MDA and persistent malaria infection




A prospective cohort study was conducted from 2013 to
2015 in six village pairs across five administrative re-
gions from the West Coast Region (WCR) to the Upper
River Region (URR). Pf prevalence as measured by poly-
merase chain reaction (PCR) ranged from 3.61% in the
West Coast Region to 19.6% in the Upper River Region.
As previously described by Mwesigwa et al. [19], the
study aimed to understand the dynamics of malaria in-
fection and the impact of annual MDA. All residents
aged more than 6 months were enrolled. Monthly sur-
veys were conducted throughout the transmission sea-
son (June to December), and in the dry season (April
2014) before MDA was implemented. In 2014 and 2015,
one round of MDA was conducted, with DHA-PQ ad-
ministered to individuals aged between 6 months and
75 years, according to weight-based dosing guidelines,
over 6 to 14 days between May and June in the six pairs
of study villages. Outcomes included incidence of clin-
ical disease, prevalence of Pf infection measured by PCR,
and factors associated with infection post-MDA.
Blood samples were collected by finger prick for
haemoglobin measurement, blood smear for malaria
diagnosis by microscopy, and molecular and serological
analysis by dried blood spot (DBS) on filter paper
(Whatman 3 Corporation, Florham Park, NJ, USA).
Clinical malaria cases were identified by passive case de-
tection (PCD) at local health facilities or in villages by
study nurses; clinical malaria was defined as history of
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fever in the previous 24 h or axillary temperature ≥
37.5 °C and a positive rapid diagnostic test (RDT) result
(Paracheck Pf, Orchid Biomedical System, India).
Serological analysis included all available samples from
the West Coast Region in Besse and N’Demban from
surveys at the start of the malaria transmission season in
July 2013 (N = 530) and at the end of the season in De-
cember 2013 (N = 522). In the Upper River Region, ana-
lysis included all samples collected in Njayel and Madina
Samako in July 2013 (N = 769), December 2013 (N =
626), April (dry season) 2014 (N = 797), and December
2014 (N = 733). These regions are at the extreme of
transmission intensity found in The Gambia—low trans-
mission in the West Coast Region and moderate trans-
mission in the Upper River Region. Samples from
clinical PCD cases were linked by study participant iden-
tification code to samples from the same individuals col-
lected during routine monthly surveys. Samples
collected as part of the Malaria Transmission Dynamics
Study and subset of samples for serological analysis are
described in Fig. 1.
Laboratory procedures
A full description of laboratory methods, including anti-
gen amino acid range, selection, and expression plat-
form, is detailed in Wu et al. [24] and Mwesigwa et al.
[25]. Briefly, serum samples were eluted from 6mm DBS
(8 μL whole blood equivalent) and prepared as a 1:500
dilution. Two wells on each plate containing only
antigen-coupled beads and sample buffer were included
to measure background signal. A pool of 22 serum sam-
ples from malaria hyper-immune individuals in The
Gambia were used as positive controls in a 6-point 5-
fold serial dilution (1:10–1:31,250) and plasma samples
from European malaria-naive adults (1:500 dilution) as
negative controls. Serum samples were processed on the
Luminex MAGPIX, with mean fluorescence intensity
(MFI) values between plates normalised according to the
protocol described in Wu et al. [24].
For diagnostic PCR, DNA was extracted from three 6-
mm DBS (4 μL whole blood equivalent) using the auto-
mated QIAxtractor robot (Qiagen). Negative and posi-
tive (3D7) controls were included to control for cross
contamination and DNA extraction efficiency, respect-
ively. Extracted DNA was used in a nested PCR, amplify-
ing multi-copy Plasmodium ribosomal RNA gene
sequences using genus- and species-specific primers. All
PCR products were run using the QIAxcel capillary elec-
trophoresis system (Qiagen).
Statistical analyses
Antibody responses were summarised at village level and
used to describe geographical differences in transmission
between the West Coast Region (low transmission) and the
Upper River Region (moderate-high transmission). Within
each region, temporal changes were assessed using antibody
responses at the start and end of transmission season (July
and December 2013) and the dry season (April 2014), rep-
resented with the methods as summarised below.
Sero-prevalence and sero-conversion rate
For antigens associated with longer-lived antibody re-
sponses [26–29]—P. falciparum merozoite surface anti-
gen 1 19-kDa carboxy-terminal region (PfMSP119), P.
falciparum apical membrane antigen 1 (PfAMA1), and
P. falciparum glutamate rich protein (PfGLURP.R2)—the
Fig. 1 Study timelines. Malaria Transmission Dynamics Study timeline shown in grey and green. Serological study timeline shown in blue for the
West Coast Region and the Upper River Region (low and moderate transmission settings, respectively). Samples for serological analysis, shown in
blue, were processed on the Luminex MAGPIX. Samples from monthly surveys (grey) were analysed using microscopy, rapid diagnostic tests
(RDTs), and polymerase chain reaction (PCR). As part of the Malaria Transmission Dynamics Study, one round of mass drug administration (MDA)
was administered from May to June in both 2014 and 2015 (2015 not shown as no samples from this year were used for serological analysis).
Transmission season (shown in red) is approximately June to December each year, and dry season from approximately January to May (shown
in yellow)
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distribution of MFI values for all serological samples was
characterised with a two-component Gaussian mixture
model to estimate the distributions of negative and posi-
tive antibody levels. Sero-positivity thresholds were de-
fined as the mean log MFI plus two standard deviations
of the negative distribution [30]. For antigens associated
with shorter-lived antibodies [21, 31]—early transcribed
membrane protein 5 (Etramp5.Ag1), gametocyte export
protein 18 (GEXP18), heat shock protein 40
(HSP40.Ag1), erythrocyte binding antigen 175 RIII-V
(EBA175), and reticulocyte binding protein homologue 2
(Rh2.2030)—sero-positivity thresholds were defined by
the mean log MFI plus three standard deviations of 71
malaria-naïve European blood donors used as negative
controls.
Age-adjusted sero-conversion rates (SCRs), the annual
rate at which sero-negative individuals become sero-
positive, were estimated for antigens associated with
long-lived antibody response (PfMSP119, PfAMA1,
PfGLURP.R2). A reverse catalytic model was fitted to
age-adjusted sero-positivity data using maximum likeli-
hood methods [28]. A common sero-reversion rate for
each antigen was assumed across all villages, which was
estimated based on fitting a single sero-catalytic model
to all individuals and fixing the sero-reversion rate in
subsequent model fits. Additionally, sero-prevalence was
estimated for children aged 1–15 years. Given the lower
likelihood of long-lived antibodies from previous malaria
exposure, sero-positivity in this age group is more likely
to reflect recent infection [20, 32]. Seasonal differences
in sero-prevalence were assessed using a two-proportion
z test, where standard errors were based on a pooled
sample population size and differences in sero-
prevalence with a significance level of 0.05 reflected by a
95% CI range that excluded zero.
Age-dependent antibody acquisition
Antibody acquisition models [33, 34] were used to esti-
mate age-dependent changes in antibody levels. Two
variants of the model were used—one assuming a con-
stant rate of increasing antibody levels with age and one
assuming differing antibody acquisition rates between
age groups (Additional file 1 - Supplementary methods).
Area Under the Antibody Acquisition Curve (AUC)
values were calculated based on the model fit for each
village and survey month, representing cumulative anti-
body levels across all ages [35]. Within-region AUCs
were compared between the start and end of transmis-
sion season as well as between regions at each time
point. The strength of evidence for observed differences
is presented as p values, derived from the posterior dis-
tributions of predicted antibody levels over two differ-
ent specified age ranges (all ages or ages 1–15 years).
Dry season antibody levels and odds of infection post-MDA
Individual antibody levels in April 2014 prior to MDA
were assessed by comparing observed and expected MFI
values as predicted by the antibody acquisition fit for in-
dividuals in the Upper River Region. For individuals with
above-average MFI values for their age group, the differ-
ence between the observed and expected log MFI was
calculated and classified to below or above median of re-
sidual MFI antibody response. Logistic regression was
used to estimate the odds of clinical malaria (passively
detected via the health facility or study nurses in the
community) or asymptomatic Pf infection (actively de-
tected using PCR from monthly survey samples) during
the transmission season following MDA (October to De-
cember 2014) amongst individuals below and above me-
dian residual dry season antibody levels, compared to
individuals at or below expected antibody responses,
allowing for clustering at the household/compound.
Multivariate analyses also adjusted for age, LLIN use,
and MDA adherence using generalised linear mixed-
effects models with the ‘glm’ and ‘glmer’ functions in the
‘lme4’ v1.1-21 package in R version 3.6.1.
Results
Sero-prevalence in children by geographical region and
transmission season
Variation in sero-prevalence between geographical region
and transmission season differed by antigen. Specifically,
between July and December (start and end of the trans-
mission season), sero-prevalence to Etramp5.Ag1 in chil-
dren aged 1–15 years in the West Coast Region increased
by 4.8% (95% CI 4.0–5.6), by 3.1% (95% CI 2.7–3.5) for
PfMSP119, by 2.9% (95% CI 2.3–3.6) for PfGLURP.R2, and
by 2.2% (95% CI 0.9–3.5) for GEXP18 (Table 1, Fig. 2,
Additional file 1 - Supplementary Table 1). In the Upper
River Region, there was statistically strong evidence for in-
creases in under-15 sero-prevalence between July and De-
cember for all antigens (Additional file 1 - Supplementary
Table 1). Mean sero-prevalence in the Upper River Region
in December 2014 (the transmission season after MDA)
was lower for PfMSP119, PfAMA1, PfGLURP.R2, Etram-
p5.Ag1, Rh2.2030, and EBA175, compared to December
2013 before implementation of MDA (Additional file 1 -
Supplementary Table 1).
Sero-conversion rate between geographical regions and
transmission seasons
Differences in sero-conversion rate between geographical
region and transmission season varied by antigen (Fig. 3,
Additional file 1 - Supplementary Table 2). At both the
start (July) and end (December) of the 2013 transmission
season, sero-conversion rates for PfMSP119, PfAMA1, and
PfGLURP.R2 were higher in the Upper River Region than
the West Coast Region. Seasonal differences in sero-
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Table 1 Sero-prevalence in children aged 1–15 years by antigen, geographical region, and transmission season. Mean sero-
prevalence estimates are shown for the West Coast Region (WCR) for July 2013 and December 2013, and the Upper River Region
(URR) for July 2013, December 2013, April 2014, and December 2014. Mean and 95% confidence intervals (parentheses) are shown
as percentages
A. Ages 1–15 years sero-prevalence (95% CI)—short-lived antibody responses
Etramp5.Ag1 GEXP18 HSP40.Ag1 Rh2.2030 EBA175
West Coast Region (WCR)
July 2013 (n = 309) 3.2% (1.9–4.5) 7.5% (5.6–9.4) 3.8% (2.4–5.1) 1.5% (0.6–2.4) 1.7% (0.8–2.6)
December 2013 (n = 315) 8.0% (6.2–9.9) 9.8% (7.7–11.8) 4.6% (3.1–6.1) 1.9% (1.0–2.9) 1.1% (0.4–1.9)
Upper River Region (URR)
July 2013 (n = 431) 5.6% (4.2–7.0) 16.4% (14.1–18.7) 7.2% (5.5–8.8) 6.8% (5.2–8.3) 5.3% (3.9–6.7)
December 2013 (n = 387) 18.5% (16.1–20.9) 22.5% (20.0–25.1) 14.4% (12.2–16.5) 17.1% (14.8–19.4) 10.5% (8.7–12.4)
April 2014 (n = 489) 13.9% (12.0–15.8) 20.7% (18.5–22.9) 14.1% (12.1–16.0) 14.3% (12.4–16.2) 9.3% (7.7–10.9)
December 2014 (n = 434) 15.4% (13.2–17.6) 25.5% (22.9–28.1) 16.0% (13.8–18.2) 13.2% (11.2–15.3) 8.6% (6.9–10.3)
B. Ages 1–15 years (95% CI)—long-lived antibody responses
PfMSP119 PfAMA1 PfGLURP.R2
West Coast Region (WCR)
July 2013 (n = 309) 1.7% (0.8–2.6) 3.8% (2.4–5.1) 3.2% (1.9–4.5)
December 2013 (n = 315) 4.8% (3.3–6.3) 4.0% (2.7–5.4) 6.1% (4.5–7.8)
Upper River Region (URR)
July 2013 (n = 431) 3.4% (2.2–4.5) 14.4% (12.2–16.6) 12.1% (10.1–14.1)
December 2013 (n = 387) 12.8% (10.7–14.8) 22.5% (20.0–25.1) 20.8% (18.3–23.3)
April 2014 (n = 489) 8.5% (7.0–10.1) 19.2% (17.0–21.4) 18.7% (16.5–20.8)
December 2014 (n = 434) 9.3% (7.5–11.0) 18.0% (15.7–20.3) 16.5% (14.3–18.7)
Fig. 2 Sero-prevalence in children ages 1–15 years by antigen, geographical region, and transmission season. Mean sero-prevalence estimates are
shown for the West Coast Region (WCR) for July 2013 (light red) and December 2013 (dark red), and the Upper River Region (URR) for July 2013
(light blue), December 2013 (dark blue), April 2014 (light green), and December 2014 (dark green), and 95% CIs are indicated by the vertical bars
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conversion rate within the same region were also ob-
served. In the West Coast Region, PfMSP119 sero-
conversion rate was three times higher in December 2013
(0.0210, 95% CI 0.0082–0.0536) than in July 2013 (0.0063,
95% CI 0.0034–0.0115), while in the Upper River Region,
PfMSP119 sero-conversion rate was four times higher in
December 2013 (0.0535, 95% CI 0.0337–0.0849) than in
July 2013 (0.0131, 95% CI 0.0088–0.0194). However, for
Fig. 3 PfMSP1.19, PfAMA1, and PfGLURP.R2 sero-conversion rates by transmission season and geographical region. Mean and 95% confidence
intervals of sero-prevalence for each age group are shown as circles and vertical lines, respectively. The mean fit of the reverse catalytic model is
shown as a solid line for the end of the transmission season (December 2013 and 2014) and as a dotted line for the dry season (April 2014) or
start of the transmission season (July 2013). Shaded regions are the 95% credible interval of the model fit
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PfAMA1 and PfGLURP.R2, seasonal differences in sero-
conversion rates were only observed in the Upper River
Region, where PfAMA1 sero-conversion rate in December
2013 was 0.0913 (95% CI 0.0735–0.1135) compared to
0.0616 (95% CI 0.0511–0.0743) in July 2013 and
PfGLURP.R2 sero-conversion rate was 0.0708 (95% CI
0.0605–0.0829) in December 2013 compared to 0.0499
(95% CI 0.0427–0.0584) in July 2013. Sero-conversion
rates for all three antigens were similar between April and
December 2014. Increases in sero-prevalence in older age
groups are not pronounced for markers associated with
short-lived antibody responses, which is an underlying as-
sumption when using sero-catalytic models. Therefore,
antibody acquisition models are used in place of sero-
conversion rates to assess age-adjusted changes in anti-
body responses based on continuous data for markers of
short-lived antibody responses.
Age-adjusted antibody acquisition by geographical
region and transmission season
All serological markers associated with shorter-lived anti-
body responses (Etramp5.Ag1, GEXP18, HSP40.Ag1,
EBA175, and Rh2.2030) showed higher antibody levels in 1–
15 year olds in the Upper River Region compared to the
West Coast Region at the end of the transmission season
(Fig. 4, Additional file 1 - Supplementary Tables 3-7). In the
Upper River Region, antibody responses to Etramp5.Ag1 in-
creased between the start and end of the transmission sea-
son amongst individuals 1–15 years (p= 0.002) (Additional
file 1 – Supplementary Table 3). However, antibody levels in
1–15 year olds for HSP40.Ag1 decreased between the start
and end of the transmission season in the West Coast Re-
gion (p= 0.01) (Additional file 1 – Supplementary Table 5).
Antibody levels to GEXP18 amongst 1–15 year olds were
also higher in the Upper River Region compared to the
West Coast Region at the start of the transmission season
(p= 0.03) (Additional file 1 – Supplementary Table 4).
For antigens associated with long-lived antibody responses
(PfMSP119, PfAMA1, and PfGLURP.R2), differences in age-
adjusted antibody acquisition amongst 1–15 year olds were
observed between the West Coast Region and Upper River
Region at the end of the 2013 transmission season (Decem-
ber) (Fig. 5, Additional file 1 - Supplementary Tables 8-10).
For PfMSP119, differences in geometric mean antibody levels
in children aged 1–15 years in the Upper River Region were
higher at the end of the transmission season compared to
the start of the season (p= 0.05) (Additional file 1 – Supple-
mentary Table 8). However, no significant differences in anti-
body levels for PfAMA1 or PfGLURP.R2 were observed
between the start and end of transmission season in the
Upper River Region. There were no within-region differences
in antibody responses to any of the antigens tested between
the 2013 transmission season and the following dry season
(April 2014).
Association between pre-MDA antibody levels and post-
MDA malaria infection
Significant decreases in under-15 sero-prevalence between
pre- and post-MDA transmission seasons (December 2013
vs. December 2014) were observed for nearly all antigens.
The largest decreases were for PfAMA1 (− 4.5%, 95% CI −
7.2, − 1.8), PfGLURP.R2 (− 4.3%, 95% CI − 6.7, − 1.8),
Rh2.2030 (− 3.9%, 95% CI − 5.9, − 1.9), PfMSP119 (− 3.5%,
95% CI − 4.9, − 2.1), and Etramp5.Ag1 (− 3.1%, 95% CI − 5.4,
− 0.9) (Additional file 1 – Supplementary Table 1). Based on
a subset of samples from 706 individuals during the 2014
transmission season, individuals with above-average antibody
levels in their age group during the dry season (April 2014)
prior to the implementation of MDA had increased odds of
clinical malaria in the 2014 transmission season (October to
December) following MDA. After adjusting for age, LLIN
use in the last 24 h, and MDA compliance, individuals with
high antibody levels to Etramp5.Ag1 had a twofold higher
odds of clinical malaria (aOR 2.05, 95% CI 1.12–3.77, p=
0.02) (Fig. 6a, Additional file 1 - Supplementary Table 11).
Dry season antibody levels to Rh2.2030 were also associated
with a twofold increase in odds of clinical malaria (OR 2.13,
95% CI 1.14–3.99, p= 0.02) after MDA (Fig. 6a, Additional
file 1 - Supplementary Table 15). While not statistically sig-
nificant, mean odds ratios indicate an increased odds of clin-
ical malaria for individuals with high antibody levels to a
number of other antigens in the panel, including PfAMA1
(aOR 1.68, 95% CI 0.91–3.10, p= 0.10), EBA175 (aOR 1.64,
95% CI 0.91–2.93, p= 0.10), HSP40.Ag1 (aOR 1.54, 95% CI
0.83–2.84, p= 0.17), and GEXP18 (aOR 1.49, 95% CI 0.80–
2.75, p= 0.21) (Additional file 1 – Supplementary Tables 17,
14, 13, and 12 respectively). There was a positive, but weaker
and non-statistically significant, association between clinical
malaria and high antibody responses to PfMSP119 (aOR 1.06,
95% CI 0.56–1.99, p= 0.86) and PfGLURP.R2 (aOR 1.19,
95% CI 0.59–2.39, p= 0.63) (Additional file 1 – Supplemen-
tary Tables 16 and 18). Associations between dry season anti-
body levels and asymptomatic infection (defined as positive
by PCR and negative by RDT) were not statistically signifi-
cant for any antigens, but mean adjusted odd ratios indicate
an increased odds of infection for individuals with high anti-
body levels to Rh2.2030 (aOR 1.60, 95% CI 0.81–3.14, p=
0.17), HSP40.Ag1 (aOR 1.64, 95% CI 0.81–3.34, p= 0.17),
PfMSP119 (aOR 1.22, 95% CI 0.63–2.34, p= 0.56), Etram-
p5.Ag1 (aOR 1.14, 95% CI 0.68–1.91, p= 0.63), and EBA175
(aOR 1.13, 95% CI 0.57–2.26, p= 0.73) (Fig. 6b, Additional
file 1 – Supplementary Tables 15, 13, 16, 11, and 14,
respectively).
Discussion
In this study, we build on previous studies evaluating in-
dividual- and household-level associations between con-
current clinical and asymptomatic malaria infection with
serological responses to a panel of antigenic targets. This
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Fig. 4 Age-dependent antibody acquisition for Etramp5.Ag1, GEXP18, HSP40.Ag1, and Rh2.2030 by geographical region and transmission season. Mean and 95%
confidence intervals of geometric mean antibody levels for each age group are shown as circles and vertical lines, respectively. Median fit of the antibody
acquisition model is shown as a solid line for the end of the transmission season (December 2013 and 2014) and as a dotted line for the dry season (April 2014)
or start of the transmission season (July 2013). Shaded regions are the 95% credible intervals of the model fit
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Fig. 5 Age-dependent antibody acquisition for EBA175, PfMSP119, PfAMA1, and PfGLURP.R2 by geographical region and transmission season. Mean
and 95% confidence intervals of geometric mean antibody levels for each age group are shown as circles and vertical lines, respectively. Median fit of
the antibody acquisition model is shown as a solid line for the end of the transmission season (December 2013 and 2014) and as a dotted line for the
dry season (April 2014) or start of the transmission season (July 2013). Shaded regions are the 95% credible intervals of the model fit
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Fig. 6 Association of pre-MDA dry season (April 2014) antibody levels and odds of a clinical malaria or b asymptomatic infection, during transmission
season post-MDA (December 2014). Odds ratios are adjusted for age, LLIN use, and MDA adherence (n = 706). Clinical malaria is defined as a clinical or
RDT confirmed case, and asymptomatic infection is defined as a PCR-positive, but clinically or RDT-negative
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study extends upon these findings to develop serological
methods for monitoring seasonal and geographical
trends in transmission, tailored for potential integration
into routine surveillance or trial evaluation. Spatio-
temporal variations in serological responses were ob-
served for several Pf antigens, likely reflecting changes in
malaria incidence as well as residual antibodies due to
prior infection. In moderate to high transmission set-
tings, higher antibody levels in the dry season due to
prior exposure are common. However, the rate at which
protective antibodies develop varies by setting. Immunity
to clinical malaria has been observed in children as
young as 5 years [36, 37], while in other transmission
settings, immunity may only develop after 10 to 15 years
of exposure [38, 39]. Children can be a useful sentinel
population for monitoring transmission, but the optimal
age range for surveillance depends on the historical pat-
terns of transmission governing population antibody re-
sponses. Most indicators and survey designs are
associated with some bias affecting the accuracy of esti-
mates. School surveys in South East Asia, where the dis-
tribution of malaria may be skewed towards older age
groups, may better reflect sero-incidence due to less
childhood exposure compared to sub-Saharan Africa.
Serological surveillance protocols can therefore be com-
bined with other routine metrics to counter potential
sampling biases.
Differences in sero-conversion rates to PfMSP119,
PfAMA1, and PfGLURP.R2 were observed between geo-
graphical regions and between the start and end of the
2013 transmission season in the Upper River Region.
However, seasonal differences in sero-conversion rates
were not detected in the West Coast Region. Long-lived
antibody responses typically reflect past exposure rather
than incidence during a single transmission season.
However, these markers have been shown to be sensitive
to changes in transmission over longer periods of time
in The Gambia [40]. Antibody acquisition models can
detect more subtle differences in the magnitude of anti-
body levels as a proxy for variation or changes in
parasite exposure. Five sero-incidence markers evaluated
in this study—Etramp5.Ag1, GEXP18, HSP40.Ag1,
EBA175, and Rh2.2030—detected geographical differ-
ences in antibody acquisition. Additionally, Etramp5.Ag1
and HSP40.Ag1 detected seasonal differences in high-
and low-transmission settings. These findings align with
previous microarray studies, where Etramp5.Ag1,
GEXP18, and HSP40.Ag1 were amongst the top 10 sero-
logical markers out of 856 Pf antigens screened found to
be most associated with recent episodes of clinical mal-
aria in Uganda and Mali [21].
Between December 2013 and April 2014, antibody
levels did not decline significantly, indicating that anti-
body decay probably occurs over a period longer than
4 months. This may be due to persistent asymptomatic
parasitaemia or infections occurring late in the transmis-
sion season. In The Gambia, antibody decay in children
has been observed for several antigens associated with
protective immunity (PfAMA1, PfMSP2, PfMSP1,
EBA175), with antibody half-lives estimated between 10
and 50 days [29, 41], and long-lived antibody secreting
cells persisting for up to 4 years [29]. However, antibody
half-lives vary between settings, ranging from 10 to 20
days in Kenya [42] and Ghana [29], 98 to 120 days in
Nigeria for EBA175 and Rh4.2 [31], and up to 225 days
in Cambodia [27] and 7 years in Thailand [26] for
PfMSP119. However, these studies focus on a limited
number of antigens. Estimates of antibody longevity for
a larger range of antigens can help inform optimal sam-
pling strategies for future serological surveillance using
multiplex assay platforms. For example, studies in Mali
have quantified antibody responses to over 2000 Pf anti-
gens on protein microarray, observing rapid declines in
antibody levels within 6 months [43].
Above-average antibody levels in the dry season before
MDA were associated with increased odds of clinical
malaria following MDA. Associations were moderate for
PfAMA1, EBA175, HSP40.Ag1, and GEXP18, but indi-
viduals with higher than average antibody levels against
Etramp5.Ag1 and Rh2.2030 had a twofold higher odds
of clinical malaria post-MDA. It is possible that serology
can identify individuals who are infected during the dry
season or experience a high frequency of exposure, lead-
ing to increased risk of clinical illness, despite remaining
below the detection limit of other diagnostics. Similar
associations were observed using parasitological end-
points, where individuals with Pf infection as measured
by PCR in the dry season had increased odds of infection
post-MDA [22]. While results were not statistically sig-
nificant, mean odds ratios suggest some association be-
tween above-average serological responses in the dry
season and asymptomatic infection as detected by PCR.
This study may be limited by the smaller sample of
asymptomatic infections (n = 55) compared to clinical
cases (n = 87). Results may also indicate that dry season
antibody levels for individuals who are later at risk of
asymptomatic infection, while still higher than average,
may be lower relative to those who develop clinical mal-
aria. The threshold antibody levels that indicate in-
creased risk of subsequent clinical malaria warrant
further study. Given that this study was not designed
specifically for the serological evaluation of MDA, ana-
lysis of a larger set of antigens or a grouping of antibody
data based on antigen expression or function during the
parasite life cycle may help delineate or categorise the
wide range of responses with respect to malaria expos-
ure, incidence, or immunity. Prospective cohort studies
measuring persistent asymptomatic parasitaemia
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throughout the dry and wet seasons across different
transmission intensities and populations would further
elucidate the dynamics between parasite density, im-
munity, and serological responses.
This study demonstrates that a diverse panel of sero-
logical markers can be used to monitor malaria exposure
(observed through long-lived antibody responses) and
recent infection incidence (through moderate to shorter-
lived antibody responses). By monitoring antibody re-
sponses in a variety of ways, such as age-specific sero-
prevalence, the magnitude of age-stratified antibody
levels, or identifying areas with clustering of above-
average antibody responses, these antigens have the po-
tential to complement conventional malaria surveillance
tools. Serological measures could be used as secondary
endpoints alongside clinical and molecular diagnostics in
the evaluation of community interventions. They could
also be used for baseline stratification of individuals or
communities according to their risk of exposure, or to
evaluate the degree to which historical or recent malaria
exposure influences study outcomes. For example, a sub-
set of the serological markers used in this study have
been used to stratify individuals in a controlled human
malaria infection (CHMI) study in The Gambia, where
individuals with serological evidence of higher malaria
exposure were found to have higher parasite growth in-
hibitory activity and control infection more effectively.
Microarray studies evaluating the combined use of mul-
tiple serological markers suggest that panels of at least
five antigens confer greater diagnostic accuracy com-
pared to a single marker, while panels of more than 20
confer only minor improvements in accuracy [21, 44].
Between-antigen variation in antibody detection will also
exist naturally; differences in the antigenicity of recom-
binant constructs could be due to sequence selection or
expression systems, or the choice of antigen isotypes and
IgG subclasses. Multi-marker diagnostic panels may be
better able to capture the breadth of antibody responses
in the population. This lends strong support for the
combined use of Pf antigens identified in this study in
future diagnostic platforms. Evaluating their agreement
and consistency with other diagnostic outcomes in inter-
vention trials, including cluster randomised trials and
surveillance studies, can help establish standardised
serological protocols usable across a variety of epidemio-
logical settings.
Conclusions
Serological markers can serve dual functions as indica-
tors of malaria exposure and incidence. By monitoring
age-specific sero-prevalence, the magnitude of age-
stratified antibody levels, or identifying groups of indi-
viduals with above-average antibody responses, these an-
tigens have the potential to complement conventional
malaria surveillance tools. Further studies, particularly
cluster randomised trials, can help establish standardised
serological protocols to reliably measure transmission
across endemic settings.
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